In this pilot study we found some evidence that use of NCB-02 enema may tend to result in greater improvements in disease activity compared to placebo in patients with mild-to-moderate distal UC. The role of NCB-02 as a novel therapy for UC should be investigated further.

In this paper, Supervised Maximum Likelihood Classification (MLC) has been nsed for analysis of remotely sensed image.The Landsat ETM+ image has used for classification. MLC is based on Bayes' classification and in this classification a pixelis assigned to a class according to its probability of belonging to a particnlar class.Mean vector and covariance metrics are the key component of MLC that can be retrieved from training data. Classification results have shown that MLC is the robnst techniqne and there is very less chances of misclassification. The classification accuracy has been achieved overall accuracy of 93.75%, producer accuracy 94%, user accuracy 96.09% and overall kappa accuracy 90.52%.

AIMTo evaluate the role of oral curcumin in inducing clinical remission in patients with mild to moderate ulcerative colitis (UC).METHODSA prospective randomized double-blind placebo-controlled trial comparing the remission inducing effect of oral curcumin and mesalamine 2.4 g with placebo and mesalamine 2.4 g in patients of ulcerative colitis with mild to moderate severity was conducted from January 2003 to March 2005. The included patients received 1 capsule thrice a day of placebo or curcumin (150 mg) for 8 wk. Patients were evaluated clinically and endoscopically at 0, 4 and 8 wk. The primary outcome was clinical remission at 8 wk and secondary outcomes were clinical response, mucosal healing and treatment failure at 8 wk. The primary analysis was intention to treat worst case scenario (ITT-WCS).RESULTSOf 300 patients with UC, 62 patients (curcumin: 29, placebo: 33) fulfilled the inclusion criteria and were randomized at baseline. Of these, 21 patients did not complete the trial, 41 patients (curcumin: 16, placebo: 25) finally completed 8 wk. There was no significant difference in rates of clinical remission (31.3% vs 27.3%, P = 0.75), clinical response (20.7% vs 36.4%, P = 0.18), mucosal healing (34.5% vs 30.3%, P = 0.72), and treatment failure (25% vs 18.5%, P = 0.59) between curcumin and placebo at 8 wk.CONCLUSIONLow dose oral curcumin at a dose of 450 mg/d was ineffective in inducing remission in mild to moderate cases of UC.

No abstract

Summary Background Differentiation between intestinal tuberculosis and Crohn's disease is difficult and may require therapeutic trial with anti‐tubercular therapy in tuberculosis‐endemic regions. Aim To evaluate the role of therapeutic trial with anti‐tubercular therapy in patients with diagnostic confusion between intestinal tuberculosis and Crohn's disease. Methods We performed retrospective‐comparative (n = 288: 131 patients who received anti‐tubercular therapy before being diagnosed as Crohn's disease and 157 intestinal tuberculosis patients) and prospective‐validation study (n = 55 patients with diagnostic confusion of intestinal tuberculosis/Crohn's disease). Outcomes assessed were global symptomatic response and endoscopic mucosal healing. Results In the derivation cohort, among those eventually diagnosed as Crohn's disease, global symptomatic response with anti‐tubercular therapy was seen in 38% at 3 months and in 37% who completed 6 months of anti‐tubercular therapy. Ninety‐four per cent of intestinal tuberculosis patients showed global symptomatic response by 3 months. Endoscopic mucosal healing was seen in only 5% of patients with Crohn's disease compared with 100% of intestinal tuberculosis patients. In the validation cohort, all the patients with intestinal tuberculosis had symptomatic response and endoscopic mucosal healing after 6 months of anti‐tubercular therapy. Among the patients with an eventual diagnosis of Crohn's disease, symptomatic response was seen in 64% at 2 months and in 31% who completed 6 months of anti‐tubercular therapy, none had mucosal healing. Conclusions Disproportionately lower mucosal healing rate despite an overall symptom response with 6 months of anti‐tubercular therapy in patients with Crohn's disease suggests a need for repeat colonoscopy for diagnosing Crohn's disease. Patients with intestinal tuberculosis showing significant symptomatic response after 2–3 months of anti‐tubercular therapy, suggest that symptom persistence after a therapeutic trial of 3 months of anti‐tubercular therapy may indicate the diagnosis of Crohn's disease.